Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Rheumatoid Arthritis

Free Subscription Articles published in Lancet Retrieve available abstracts of 17 articles: HTML format

Single Articles

October 2024
1. CARTELLA I, Palazzini M, Sirico D, Buono A, et al
   Hypertrophic cardiomyopathy secondary to hydroxychloroquine toxicity in a patient with rheumatoid arthritis.
   Lancet. 2024;404:1560.
   PubMed    
   
   
   August 2024
2. FISHER BA, Mariette X, Papas A, Grader-Beck T, et al
   Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
   Lancet. 2024;404:540-553.
   PubMed     Abstract available
   
   
   
3. COLAFRANCESCO S, Priori R
   Sjogren's disease: a new era for clinical trials?
   Lancet. 2024;404:498-499.
   PubMed    
   
   
   February 2024
4. VAN DER HELM-VAN MIL AHM
   Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
   Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
   PubMed    
   
   
   
5. RECH J, Tascilar K, Hagen M, Kleyer A, et al
   Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
   Lancet. 2024 Feb 13:S0140-6736(23)02650-8. doi: 10.1016/S0140-6736(23)02650.
   PubMed     Abstract available
   
   
   
6. COPE AP, Jasenecova M, Vasconcelos JC, Filer A, et al
   Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
   Lancet. 2024 Feb 13:S0140-6736(23)02649-1. doi: 10.1016/S0140-6736(23)02649.
   PubMed     Abstract available
   
   
   November 2023
7. DI MATTEO A, Bathon JM, Emery P
   Rheumatoid arthritis.
   Lancet. 2023;402:2019-2033.
   PubMed     Abstract available
   
   
   June 2023
8. SAAVEDRA FT, Sierra LL, Zuluaica AM, Botero EC, et al
   Diagnosing Caplan syndrome in a patient with silicosis and rheumatoid arthritis: imaging shows miliary pattern and cavity lung lesions.
   Lancet. 2023;401:2148.
   PubMed    
   
   
   May 2023
9. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
   Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
   Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
   PubMed     Abstract available
   
   
   February 2023
10. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
    PubMed     Abstract available
    
    
    September 2022
11. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
    Lancet. 2022;400:808-809.
    PubMed    
    
    
    
12. DYBALL S, Parker B, Bruce IN
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
    Lancet. 2022;400:807-808.
    PubMed    
    
    
    July 2022
13. KRIJBOLDER DI, Verstappen M, van Dijk BT, Dakkak YJ, et al
    Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial
    Lancet. 2022;400:283-294.
    PubMed     Abstract available
    
    
    
14. RECH J, Schett G
    Towards preventive treatment of rheumatoid arthritis.
    Lancet. 2022;400:253-255.
    PubMed    
    
    
    January 2022
15. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    PubMed    
    
    
    
16. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    PubMed     Abstract available
    
    
    August 2021
17. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Rheumatoid Arthritis is free of charge.